H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Aligos Therapeutics today and set a price target of $50.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Trucchio has given his Buy rating due to a combination of factors tied to Aligos Therapeutics’ lead asset and trial progress. The first interim look at the Phase 2 B-SUPREME study showed that pevifoscorvir met safety expectations, avoided futility triggers, and gained FDA Fast Track status, while an independent board supported expanding enrollment to strengthen the statistical robustness of the results.
Trucchio also underscores that the increase in sample size stems from differences in HBV DNA assay sensitivity versus historical tenofovir data, rather than from weaker drug performance, which he views as a constructive, data-driven adjustment. Looking ahead, he highlights the potential for clearer efficacy separation from tenofovir in the HBeAg+ subgroup and the value of the planned open-label phase for additional viral suppression and antigen-reduction data, supporting his reiterated Buy rating and $50 price target on ALGS.
Trucchio covers the Healthcare sector, focusing on stocks such as Gossamer Bio, Atai Beckley N.V., and Arrowhead Pharmaceuticals. According to TipRanks, Trucchio has an average return of 23.8% and a 48.07% success rate on recommended stocks.